Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Diessner, J ^a   Bruttel, V ^a   Stein, R G ^a   Horn, E ^a   M Hausler S F ^a   Dietl, J ^a   Honig A ^a   Wischhusen, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Breast cancer; HER2; T DM1; Targeted therapy; Tumor stem cells

Indexed keywords

CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UVOMORULIN; EMTANSINE; LEUKOCYTE ANTIGEN; MAYTANSINE; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOPHAGY; BREAST METASTASIS; CANCER CELL CULTURE; CANCER STEM CELL; CELL DEATH; CELL DEDIFFERENTIATION; CELL DENSITY; CELL DIFFERENTIATION; CELL SURVIVAL; CLONOGENESIS; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL CLONE; CELL MEMBRANE; DOSE RESPONSE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; TIME; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CLONE CELLS; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FEMALE; HUMANS; KILLER CELLS, NATURAL; MAYTANSINE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHENOTYPE; RECEPTOR, ERBB-2; TIME FACTORS; YOUNG ADULT;

EID: 84897431499     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.115     Document Type: Article

References (60)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
2. Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2010; 285: 7035-7044.
3. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005; 103: 1770-1777.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2012; 3: 224-237.
6. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013; 73: 1635-1646.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
9. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
11. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003; 2: 1113-1120.
12. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008; 6: 25.
13. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
14. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446.
15. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122: 1066-1075.
16. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hä usler S, Ossadnik M et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 2009; 69: 8058-8066.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
18. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 2012; 122: 2066-2078.
19. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
20. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011; 32: 650-658.
21. Sutherland CM, Mather FJ, Carter RD, Cerise EJ, Krementz ET. Breast cancer as analyzed by the human tumor stem cell assay. Surgery 1983; 94: 370-375.
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
23. Harless WW. Cancer treatments transform residual cancer cell phenotype. Cancer Cell Int 2011; 11: 1.
24. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012; 47: 570-584.
25. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490: 412-416.
26. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009; 69: 2887-2895.
27. Yu TW, Bai L, Clade D, Hoffmann D, Toelzer S, Trinh KQ et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc Natl Acad Sci USA 2002; 99: 7968-7973.
28. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5: 543-549.
29. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14: 2436-2446.
30. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52: 127-131.
31. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006; 66: 4426-4433.
32. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010; 70: 2528-2537.
33. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975; 189: 1002-1005.
34. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-2251.
35. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 5268-5282.
36. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012; 30: 3234-3241.
37. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 2010; 4: 35-41.
38. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 2002; 13: 1743-1748.
39. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68: 5706-5715.
40. Brisken C, Duss S. Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev 2007; 3: 147-156.
41. Diessner J, Bruttel V, Becker K, Pawlik M, Stein R, Häusler S et al. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am J Cancer Res 2013; 3: 211-220.
42. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
43. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci 2005; 118(Pt 5): 873-887.
44. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999; 112(Pt 24): 4557-4568.
45. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005; 115: 1765-1776.
46. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013; 368: 651-662.
47. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PloS One 2010; 5: e10240.
48. Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C, Nicolas V et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2012; 32: 22261-22272.
49. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011; 10: 3871-3885.
50. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010; 285: 10850-10861.
51. Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res 2013; 73: 3-7.
52. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 2011; 286: 6587-6601.
53. Chen S, Li X, Feng J, Chang Y, Wang Z, Wen A. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells. Med Hypotheses 2011; 77: 206-208.
54. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69: 1229-1240.
55. Vazquez-Martin A, Lopez-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011; 14: 212-223.
56. Li Z, Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 2010; 345: 21-30.
57. Madeo F, Tavernarakis N, Kroemer G. Can autophagy promote longevity? Nat Cell Biol 2010; 12: 842-846.
58. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med 2011; 208: 455-467.
59. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-666.
60. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.